WaferGen Biosystems

WaferGen Bio-systems, Inc. is a biotechnology company that offers innovative genomic technology solutions for single-cell analysis and clinical research. The ICELL8TM Single-Cell System is a revolutionary platform which can isolate thousands of single cells and processes specific cells for analysis, including Next Generation Sequencing. The system has demonstrated unbiased isolation of up to 1,800 single cells ranging from 5-100 µm in size on a single chip, including single cells from solid tumors, brain cells, pulmonary airway cells, and multiple cell lines. The SmartChipTM platform can be used for profiling and validating molecular biomarkers, and can perform massively-parallel single-plex PCR for one-step target enrichment and library preparation for clinical NGS. The Apollo 324TM system can be used to process DNA and RNA from clinical samples to next generation sequencing ready libraries. These technologies offer a powerful set of tools for biological analysis at the molecular and single-cell level in the life sciences, pharmaceutical, and clinical laboratory industries.
Fremont, US
WaferGen Biosystems was founded in 2003 and is headquartered in Fremont, US

Key People at WaferGen Biosystems

Jude Dunne

Jude Dunne

Vice President Product Development

WaferGen Biosystems Office Locations

WaferGen Biosystems has offices in Fremont and Luxembourg
Fremont, US (HQ)
34700 Campus Dr
Luxembourg, LU
84 Val Fleuri

WaferGen Biosystems Data and Metrics

WaferGen Biosystems Summary

Founding Date


Total Funding

$56.9 m

WaferGen Biosystems Financial Metrics

USDFY, 2013FY, 2014FY, 2015


10.7 m14.7 m15.2 m

Accounts Receivable

367.3 k1.5 m2.2 m


350.5 k379.5 k404 k

Current Assets

11.7 m17.4 m19.8 m


269.6 k869.3 k1.1 m


990 k990 k

Total Assets

12 m20.7 m22.9 m

Accounts Payable

980.9 k1.5 m2 m

Current Liabilities

2.4 m3.8 m4.3 m

Retained Earnings

(80.8 m)(91.5 m)(106.8 m)

Total Equity

15.7 m

Financial Leverage

1.5 x
USDFY, 2013FY, 2014FY, 2015

Net Income

(16.3 m)(10.7 m)(15.3 m)

Depreciation and Amortization

692.5 k821.8 k881 k

Accounts Receivable

(60.9 k)(1.1 m)(720 k)


280.4 k819.3 k(1.3 m)

Accounts Payable

506.5 k513.3 k535 k

Cash From Operating Activities

(8.2 m)(10.3 m)(14.6 m)

Purchases of PP&E

(91.5 k)(334.6 k)(308 k)

Cash From Investing Activities

(525 k)(2.3 m)(308 k)

Cash From Financing Activities

13.3 m16.6 m15.5 m

Interest Paid

4.3 k70.8 k23 k

Income Taxes Paid

28.6 k3.1 k2 k

Traffic Overview of WaferGen Biosystems

WaferGen Biosystems Online and Social Media Presence

WaferGen Biosystems Company Life and Culture

You may also be interested in